Frank Dieterle
Novartis
Network
Latest external collaboration on country level. Dive into details by clicking on the dots.
Publication
Featured researches published by Frank Dieterle.
Nature Biotechnology | 2010
Vishal S. Vaidya; Josef S. Ozer; Frank Dieterle; Fitz B. Collings; Victoria Ramírez; Sean P. Troth; Nagaraja Muniappa; Douglas Thudium; David Gerhold; Daniel J. Holder; Norma A. Bobadilla; Estelle Marrer; Elias Perentes; André Cordier; Jacky Vonderscher; Gerard Maurer; Peter L. Goering; Frank D. Sistare; Joseph V. Bonventre
Kidney toxicity accounts both for the failure of many drug candidates as well as considerable patient morbidity. Whereas histopathology remains the gold standard for nephrotoxicity in animal systems, serum creatinine (SCr) and blood urea nitrogen (BUN) are the primary options for monitoring kidney dysfunction in humans. The transmembrane tubular protein kidney injury molecule-1 (Kim-1) was previously reported to be markedly induced in response to renal injury. Owing to the poor sensitivity and specificity of SCr and BUN, we used rat toxicology studies to compare the diagnostic performance of urinary Kim-1 to BUN, SCr and urinary N-acetyl-β-D-glucosaminidase (NAG) as predictors of kidney tubular damage scored by histopathology. Kim-1 outperforms SCr, BUN and urinary NAG in multiple rat models of kidney injury. Urinary Kim-1 measurements may facilitate sensitive, specific and accurate prediction of human nephrotoxicity in preclinical drug screens. This should enable early identification and elimination of compounds that are potentially nephrotoxic.
Nature Biotechnology | 2010
Joseph V. Bonventre; Vishal S. Vaidya; Robert Schmouder; Peter U. Feig; Frank Dieterle
There is a paucity of biomarkers that reliably detect nephrotoxicity. The Predictive Safety Testing Consortium (PSTC) faced several challenges in identifying novel safety biomarkers in the renal setting.
Nature Biotechnology | 2010
Frank Dieterle; Frank D. Sistare; Federico Goodsaid; Marisa Papaluca; Josef S. Ozer; Craig P. Webb; William Baer; Anthony J. Senagore; Matthew J. Schipper; Jacky Vonderscher; Stefan Sultana; David Gerhold; Jonathan A. Phillips; Gerard Maurer; Kevin Carl; David Laurie; Ernie Harpur; Manisha Sonee; Daniela Ennulat; Dan Holder; Dina Andrews-Cleavenger; Yi Zhong Gu; Karol L. Thompson; Peter L. Goering; Jean Marc Vidal; Eric Abadie; Romaldas Mačiulaitis; David Jacobson-Kram; Albert DeFelice; Elizabeth Hausner
The first formal qualification of safety biomarkers for regulatory decision making marks a milestone in the application of biomarkers to drug development. Following submission of drug toxicity studies and analyses of biomarker performance to the Food and Drug Administration (FDA) and European Medicines Agency (EMEA) by the Predictive Safety Testing Consortiums (PSTC) Nephrotoxicity Working Group, seven renal safety biomarkers have been qualified for limited use in nonclinical and clinical drug development to help guide safety assessments. This was a pilot process, and the experience gained will both facilitate better understanding of how the qualification process will probably evolve and clarify the minimal requirements necessary to evaluate the performance of biomarkers of organ injury within specific contexts.
Nature Biotechnology | 2010
Frank Dieterle; Elias Perentes; André Cordier; Daniel Robert Roth; Pablo Verdes; Olivier Grenet; Serafino Pantano; Pierre Moulin; Daniel Wahl; Andreas Mahl; Peter End; Frank Staedtler; Francois Legay; Kevin Carl; David Laurie; Salah-Dine Chibout; Jacky Vonderscher; Gerard Maurer
Earlier and more reliable detection of drug-induced kidney injury would improve clinical care and help to streamline drug-development. As the current standards to monitor renal function, such as blood urea nitrogen (BUN) or serum creatinine (SCr), are late indicators of kidney injury, we conducted ten nonclinical studies to rigorously assess the potential of four previously described nephrotoxicity markers to detect drug-induced kidney and liver injury. Whereas urinary clusterin outperformed BUN and SCr for detecting proximal tubular injury, urinary total protein, cystatin C and β2-microglobulin showed a better diagnostic performance than BUN and SCr for detecting glomerular injury. Gene and protein expression analysis, in-situ hybridization and immunohistochemistry provide mechanistic evidence to support the use of these four markers for detecting kidney injury to guide regulatory decision making in drug development. The recognition of the qualification of these biomarkers by the EMEA and FDA will significantly enhance renal safety monitoring.
Nature Biotechnology | 2010
Josef S. Ozer; Frank Dieterle; Sean P. Troth; Elias Perentes; André Cordier; Pablo Verdes; Frank Staedtler; Andreas Mahl; Olivier Grenet; Daniel Robert Roth; Daniel Wahl; Francois Legay; Daniel J. Holder; Zoltan Erdos; Katerina Vlasakova; Hong Jin; Yan Yu; Nagaraja Muniappa; Tom Forest; Holly Clouse; Spencer Reynolds; Wendy J. Bailey; Douglas Thudium; Michael J Topper; Thomas R. Skopek; Joseph F. Sina; Warren E. Glaab; Jacky Vonderscher; Gerard Maurer; Salah-Dine Chibout
The Predictive Safety Testing Consortiums first regulatory submission to qualify kidney safety biomarkers revealed two deficiencies. To address the need for biomarkers that monitor recovery from agent-induced renal damage, we scored changes in the levels of urinary biomarkers in rats during recovery from renal injury induced by exposure to carbapenem A or gentamicin. All biomarkers responded to histologic tubular toxicities to varied degrees and with different kinetics. After a recovery period, all biomarkers returned to levels approaching those observed in uninjured animals. We next addressed the need for a serum biomarker that reflects general kidney function regardless of the exact site of renal injury. Our assay for serum cystatin C is more sensitive and specific than serum creatinine (SCr) or blood urea nitrogen (BUN) in monitoring generalized renal function after exposure of rats to eight nephrotoxicants and two hepatotoxicants. This sensitive serum biomarker will enable testing of renal function in animal studies that do not involve urine collection.
Nature Biotechnology | 2010
Frank D. Sistare; Frank Dieterle; Sean P. Troth; Daniel J. Holder; David Gerhold; Dina Andrews-Cleavenger; William Baer; Graham Betton; Denise I. Bounous; Kevin Carl; Nathaniel Collins; Peter L. Goering; Federico Goodsaid; Yi Zhong Gu; Valerie Guilpin; Ernie Harpur; Alita Hassan; David Jacobson-Kram; Peter Kasper; David Laurie; Beatriz Silva Lima; Romaldas Mačiulaitis; William Mattes; Gerard Maurer; Leslie Obert; Josef S. Ozer; Marisa Papaluca-Amati; Jonathan A. Phillips; Mark Pinches; Matthew J. Schipper
Application of any new biomarker to support safety-related decisions during regulated phases of drug development requires provision of a substantial data set that critically assesses analytical and biological performance of that biomarker. Such an approach enables stakeholders from industry and regulatory bodies to objectively evaluate whether superior standards of performance have been met and whether specific claims of fit-for-purpose use are supported. It is therefore important during the biomarker evaluation process that stakeholders seek agreement on which critical experiments are needed to test that a biomarker meets specific performance claims, how new biomarker and traditional comparators will be measured and how the resulting data will be merged, analyzed and interpreted.
Toxicological Sciences | 2010
Dana Hoffmann; Melanie Adler; Vishal S. Vaidya; Eva Rached; Laoighse Mulrane; William M. Gallagher; John J. Callanan; Jean C. Gautier; Katja Matheis; Frank Staedtler; Frank Dieterle; Arnd Brandenburg; Alexandra Sposny; Philip Hewitt; Heidrun Ellinger-Ziegelbauer; Joseph V. Bonventre; Wolfgang Dekant; Angela Mally
The kidney is one of the main targets of drug toxicity, but early detection of renal damage is often difficult. As part of the InnoMed PredTox project, a collaborative effort aimed at assessing the value of combining omics technologies with conventional toxicology methods for improved preclinical safety assessment, we evaluated the performance of a panel of novel kidney biomarkers in preclinical toxicity studies. Rats were treated with a reference nephrotoxin or one of several proprietary compounds that were dropped from drug development in part due to renal toxicity. Animals were dosed at two dose levels for 1, 3, and 14 days. Putative kidney markers, including kidney injury molecule-1 (Kim-1), lipocalin-2 (Lcn2), clusterin, and tissue inhibitor of metalloproteinases-1, were analyzed in kidney and urine using quantitative real-time PCR, ELISA, and immunohistochemistry. Changes in gene/protein expression generally correlated well with renal histopathological alterations and were frequently detected at earlier time points or at lower doses than the traditional clinical parameters blood urea nitrogen and serum creatinine. Urinary Kim-1 and clusterin reflected changes in gene/protein expression and histopathological alterations in the target organ in the absence of functional changes. This confirms clusterin and Kim-1 as early and sensitive, noninvasive markers of renal injury. Although Lcn2 did not appear to be specific for kidney toxicity, its rapid response to inflammation and tissue damage in general may suggest its utility in routine toxicity testing.
Pharmacogenomics | 2006
Götz Schlotterbeck; Alfred Ross; Frank Dieterle; Hans Martin Senn
The state-of-the-art of nuclear magnetic resonance spectroscopy, mass spectrometry and statistical tools for the acquisition and evaluation of complex multidimensional spectroscopic data in metabolic profiling is reviewed in this article. The continuous evolution of the sensitivity, precision and throughput has made these technologies powerful and extremely robust tools for application in systems biology, pharmaceutical and diagnostics research. Particular emphasis is also given to the collection and storage of biological samples that are subjected to metabolite profiling. Selected examples from preclinical and clinical applications are paradigmatically shown. These illustrate the power of the profiling technologies for characterizing the metabolic phenotype of healthy, diseased and treated subjects. The complexity of disease and drug treatment is asking for an adequate response by integrated and comprehensive metabolite profiling approaches that allow the discovery of new combinations of metabolic biomarkers.
Chemical Biology & Drug Design | 2007
Estelle Marrer; Frank Dieterle
Biomarkers have been a buzz word in drug development for the last 5 years. But where do we stand now? This perspective article will demonstrate to which extent biomarkers have impacted drug development and the use of drugs. In particular, the different types of biomarkers, their identification, validation and use in different phases of drug development from drug discovery, to approval, to clinical application will be discussed as well as the state‐of‐the‐art biomarker technologies and promising future methods. The high interest in biomarkers has generated the need for development of new technologies and refinement of existing ones. Besides discussing their perspectives of applications, the present article also illustrates the future of biomarker development in terms of qualification for regulatory use and co‐development.
Expert Opinion on Drug Metabolism & Toxicology | 2009
Patrick Y Muller; Frank Dieterle
Limited sensitivity and limited target organ specificity are the major drawbacks for most peripheral clinical pathology parameters traditionally used for monitoring organ integrity both during preclinical toxicological assessment and clinical safety testing of investigational drugs. Several novel toxicity biomarkers have emerged as sensitive tools for detection, monitoring, quantification and prediction of solid organ toxicity. These tissue-specific, non-invasive biomarkers may provide valuable information for decision making during toxicological assessment and may be used for sensitive and specific target organ monitoring during clinical trials. This review critically discusses the opportunities and limitations of these biomarkers with respect to their translation into (first-in-human) clinical trials. A comprehensive overview is provided on serum- and urine-based biomarkers for hepatotoxicity, nephrotoxicity, cardiotoxicity, gonadotoxicity, pancreatic toxicity, vascular toxicity and phospholipidosis including species-specific assay availabilities and sampling regimens. In addition, the current regulatory status is presented and discussed in view of recent changes in regulatory acceptance by health authorities.